competitive antagonist

Caffeine has recently been found to also be a competitive antagonist.

The most frequently used drug is naltrexone, a long-acting competitive antagonist.

Competitive antagonists, if they compete with the main drug to bind with the receptor.

The effects of a competitive antagonist may be overcome by increasing the concentration of agonist.

Presence of a competitive antagonist will shift an agonism dose-response curve to the right.

Competitive antagonists at serotonergic (5-hydroxytryptamine-3 or 5-HT3 subtype) receptors.

Aldosterone antagonists: spironolactone, which is a competitive antagonist of aldosterone.

In doing this it is also acting as a competitive antagonist for the EGF ligand.

The interleukin-1 receptor antagonist, IL-1Ra is an example of a competitive antagonist.

Competitive antagonists at dopaminergic (D2 subtype) receptors: Phenothiazines.

Saclofen is a competitive antagonist for the GABA receptor.

These data correspond well with previously reported data for this compound [ 22 ] and verify the competitive antagonist action of lerisetron.

The main effect induced by vinclozolin is related to its antiandrogenic activity and its ability to act as a competitive antagonist at the androgen receptor.

Would-be developers of anti-cancer drugs have continued to seek competitive antagonists which might block one or another stage in the synthesis of pyrimidines and purines.

It is a tricyclic aryl derivative that acts as a competitive antagonist at the CB cannabinoid receptor.

The azabicyclic ring of the competitive antagonist granisetron is located close to R92 and the aromatic rings lie close to W90.

Bicuculline is a light-sensitive competitive antagonist of GABA receptors.

Below are some of the more common agents that act as competitive antagonists against acetylcholine at the site of postsynaptic acetylcholine receptors.

The first competitive antagonist, capsazepine, was first described in 1990, since then development of novel TRPV1 antagonists has come a long way.

Sulfonamides are structural analogs and competitive antagonists of para-aminobenzoic acid (PABA).

It acts as a non-depolarizing competitive antagonist at the nicotinic acetylcholine receptor, is short-acting, and is given intravenously.

The receptor occupancy model, which describes agonist and competitive antagonists, was built on the work of Langley, Hill and Clark.

The H antagonists are competitive antagonists of histamine at the parietal cell H receptor.

To avoid this persisting side effects of TRPV1 agonists, a focused consideration has been given to competitive antagonists as novel analgesic drugs.

Cimetidine is a competitive antagonist at the dihydrotestosterone (DHT) receptor, leading to exaggerated effects of estrogens.